Is Product Infatuation the Death Knell for Platforms?
Executive Summary
Incyte Genomics Inc., the creator of the database model and practically the ur-platform company, has suddenly decided to turn into a drug discovery company--changing top management to do so. Other firms that decided years ago to leverage genetic information to create drugs have far higher valuations than Incyte--indeed biotechs reporting product revenues get valuation multiples on sales that are twice as high as those platform companies command --and about triple the multiples that Big Pharma receives on its sales.You may also be interested in...
For 2001, A Top Eleven List
2001 was a mixed year for health-care manufacturers, characterized by real advances in cardiac device therapies, the maturing of the biotech and generics sectors, and the continued embattlement of Big Pharma. Here's the staff of IN VIVO's list of the most important trends.
Viatris Will Tread A Different Path
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
EU Single Patent System On Course For 2020
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports